The role of high-dose-rate brachytherapy boost in breast-conserving therapy: Long-term results of the Hungarian National Institute of Oncology

C. Polgár, Levente Jánváry, T. Major, A. Somogyi, Nagy Z. Takácsi, Georgina Fröhlich, J. Fodor

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Aim: To report the long-term results of high-dose-rate (HDR) brachytherapy (BT) boost for breast cancer patients treated with conservative surgery and radiotherapy. Materials and methods: Between 1995 and 2007, 100 early-stage breast cancer patients received an HDR BT boost after conservative surgery and whole breast irradiation. Ten patients (10%) received a single-fraction HDR boost of 8-10.35 Gy using rigid needles, while 90 (90%) were treated with a fractionated multi-catheter HDR BT boost. The latter consisted of 3 × 4 Gy (n = 19), 3 × 4.75 Gy (n = 70), and 2 × 6.4 Gy (n = 1). Breast cancer related events, cosmetic results and side effects were assessed. Results: At a median follow-up time of 94 months (range: 8-152) only 7 (7%) ipsilateral breast failures were observed for a 5- and 8-year actuarial rate of 4.5 and 7.0%, respectively. The 8-year disease-free, cancer-specific, and overall survival was 76.1, 82.8, and 80.4%, respectively. Cosmetic outcome was rated excellent in 17%, good in 39%, fair in 33%, and poor in 11%. Data on late radiation side effects were available for 91 patients (91%). Grade 3 fibrosis and grade 3 telangiectasia occurred in 6 (6.6%) and 2 (2.2%) patients, respectively. In univariate analysis only positive margin status had a significant negative effect on local control. Conclusions: HDR BT boost using multi-catheter implants produce excellent long-term local tumour control with acceptable cosmetic outcome and low rate of grade 3 late radiation side effects.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalReports of Practical Oncology and Radiotherapy
Volume15
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

Brachytherapy
Breast
Cosmetics
Radiation Effects
Breast Neoplasms
Catheters
Therapeutics
Telangiectasis
Needles
Neoplasms
Fibrosis
Radiotherapy
Survival

Keywords

  • Boost
  • Breast-conserving therapy
  • High-dose-rate brachytherapy
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

@article{8705f9ebdb7040fa8d586385e42ba9ae,
title = "The role of high-dose-rate brachytherapy boost in breast-conserving therapy: Long-term results of the Hungarian National Institute of Oncology",
abstract = "Aim: To report the long-term results of high-dose-rate (HDR) brachytherapy (BT) boost for breast cancer patients treated with conservative surgery and radiotherapy. Materials and methods: Between 1995 and 2007, 100 early-stage breast cancer patients received an HDR BT boost after conservative surgery and whole breast irradiation. Ten patients (10{\%}) received a single-fraction HDR boost of 8-10.35 Gy using rigid needles, while 90 (90{\%}) were treated with a fractionated multi-catheter HDR BT boost. The latter consisted of 3 × 4 Gy (n = 19), 3 × 4.75 Gy (n = 70), and 2 × 6.4 Gy (n = 1). Breast cancer related events, cosmetic results and side effects were assessed. Results: At a median follow-up time of 94 months (range: 8-152) only 7 (7{\%}) ipsilateral breast failures were observed for a 5- and 8-year actuarial rate of 4.5 and 7.0{\%}, respectively. The 8-year disease-free, cancer-specific, and overall survival was 76.1, 82.8, and 80.4{\%}, respectively. Cosmetic outcome was rated excellent in 17{\%}, good in 39{\%}, fair in 33{\%}, and poor in 11{\%}. Data on late radiation side effects were available for 91 patients (91{\%}). Grade 3 fibrosis and grade 3 telangiectasia occurred in 6 (6.6{\%}) and 2 (2.2{\%}) patients, respectively. In univariate analysis only positive margin status had a significant negative effect on local control. Conclusions: HDR BT boost using multi-catheter implants produce excellent long-term local tumour control with acceptable cosmetic outcome and low rate of grade 3 late radiation side effects.",
keywords = "Boost, Breast-conserving therapy, High-dose-rate brachytherapy, Radiotherapy",
author = "C. Polg{\'a}r and Levente J{\'a}nv{\'a}ry and T. Major and A. Somogyi and Tak{\'a}csi, {Nagy Z.} and Georgina Fr{\"o}hlich and J. Fodor",
year = "2010",
month = "1",
doi = "10.1016/j.rpor.2010.01.002",
language = "English",
volume = "15",
pages = "1--7",
journal = "Reports of Practical Oncology and Radiotherapy",
issn = "1507-1367",
publisher = "Elsevier Urban and Partner sp. z o.o.",
number = "1",

}

TY - JOUR

T1 - The role of high-dose-rate brachytherapy boost in breast-conserving therapy

T2 - Long-term results of the Hungarian National Institute of Oncology

AU - Polgár, C.

AU - Jánváry, Levente

AU - Major, T.

AU - Somogyi, A.

AU - Takácsi, Nagy Z.

AU - Fröhlich, Georgina

AU - Fodor, J.

PY - 2010/1

Y1 - 2010/1

N2 - Aim: To report the long-term results of high-dose-rate (HDR) brachytherapy (BT) boost for breast cancer patients treated with conservative surgery and radiotherapy. Materials and methods: Between 1995 and 2007, 100 early-stage breast cancer patients received an HDR BT boost after conservative surgery and whole breast irradiation. Ten patients (10%) received a single-fraction HDR boost of 8-10.35 Gy using rigid needles, while 90 (90%) were treated with a fractionated multi-catheter HDR BT boost. The latter consisted of 3 × 4 Gy (n = 19), 3 × 4.75 Gy (n = 70), and 2 × 6.4 Gy (n = 1). Breast cancer related events, cosmetic results and side effects were assessed. Results: At a median follow-up time of 94 months (range: 8-152) only 7 (7%) ipsilateral breast failures were observed for a 5- and 8-year actuarial rate of 4.5 and 7.0%, respectively. The 8-year disease-free, cancer-specific, and overall survival was 76.1, 82.8, and 80.4%, respectively. Cosmetic outcome was rated excellent in 17%, good in 39%, fair in 33%, and poor in 11%. Data on late radiation side effects were available for 91 patients (91%). Grade 3 fibrosis and grade 3 telangiectasia occurred in 6 (6.6%) and 2 (2.2%) patients, respectively. In univariate analysis only positive margin status had a significant negative effect on local control. Conclusions: HDR BT boost using multi-catheter implants produce excellent long-term local tumour control with acceptable cosmetic outcome and low rate of grade 3 late radiation side effects.

AB - Aim: To report the long-term results of high-dose-rate (HDR) brachytherapy (BT) boost for breast cancer patients treated with conservative surgery and radiotherapy. Materials and methods: Between 1995 and 2007, 100 early-stage breast cancer patients received an HDR BT boost after conservative surgery and whole breast irradiation. Ten patients (10%) received a single-fraction HDR boost of 8-10.35 Gy using rigid needles, while 90 (90%) were treated with a fractionated multi-catheter HDR BT boost. The latter consisted of 3 × 4 Gy (n = 19), 3 × 4.75 Gy (n = 70), and 2 × 6.4 Gy (n = 1). Breast cancer related events, cosmetic results and side effects were assessed. Results: At a median follow-up time of 94 months (range: 8-152) only 7 (7%) ipsilateral breast failures were observed for a 5- and 8-year actuarial rate of 4.5 and 7.0%, respectively. The 8-year disease-free, cancer-specific, and overall survival was 76.1, 82.8, and 80.4%, respectively. Cosmetic outcome was rated excellent in 17%, good in 39%, fair in 33%, and poor in 11%. Data on late radiation side effects were available for 91 patients (91%). Grade 3 fibrosis and grade 3 telangiectasia occurred in 6 (6.6%) and 2 (2.2%) patients, respectively. In univariate analysis only positive margin status had a significant negative effect on local control. Conclusions: HDR BT boost using multi-catheter implants produce excellent long-term local tumour control with acceptable cosmetic outcome and low rate of grade 3 late radiation side effects.

KW - Boost

KW - Breast-conserving therapy

KW - High-dose-rate brachytherapy

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=77549083225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77549083225&partnerID=8YFLogxK

U2 - 10.1016/j.rpor.2010.01.002

DO - 10.1016/j.rpor.2010.01.002

M3 - Article

AN - SCOPUS:77549083225

VL - 15

SP - 1

EP - 7

JO - Reports of Practical Oncology and Radiotherapy

JF - Reports of Practical Oncology and Radiotherapy

SN - 1507-1367

IS - 1

ER -